[{"orgOrder":0,"company":"Almirall","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Finasteride","moa":"Steroid 5-alpha-reductase 2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Almirall \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Finasteride","moa":"||Steroid 5-alpha-reductase 2","graph1":"Urology","graph2":"Approved FDF","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prague Scientific \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Prague Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Finasteride","moa":"||Steroid 5-alpha-reductase 2","graph1":"Urology","graph2":"Approved FDF","graph3":"Veru","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Veru \/ Blue Water Vaccines","highestDevelopmentStatusID":"15","companyTruncated":"Veru \/ Blue Water Vaccines"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Finasteride","moa":"||Steroid 5-alpha-reductase 2","graph1":"Urology","graph2":"Approved FDF","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"IQVIA","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Finasteride","moa":"||Steroid 5-alpha-reductase 2","graph1":"Urology","graph2":"Approved FDF","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Blue Water Vaccines \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Blue Water Vaccines \/ IQVIA"},{"orgOrder":0,"company":"Onconetix","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Finasteride","moa":"||Steroid 5-alpha-reductase 2","graph1":"Urology","graph2":"Approved FDF","graph3":"Onconetix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconetix \/ Blue Water Vaccines","highestDevelopmentStatusID":"15","companyTruncated":"Onconetix \/ Blue Water Vaccines"},{"orgOrder":0,"company":"Triple Hair","sponsor":"Akums Drugs & Pharmaceuticals Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Finasteride","moa":"||Steroid 5-alpha-reductase 2","graph1":"Dermatology","graph2":"Phase II","graph3":"Triple Hair","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Triple Hair \/ Akums Drugs & Pharmaceuticals Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Triple Hair \/ Akums Drugs & Pharmaceuticals Ltd"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Finasteride","moa":"Steroid 5-alpha-reductase 2","graph1":"Dermatology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Finasteride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Finasteride

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Finasteride is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 21, 2010

                          Lead Product(s) : Finasteride

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          02

                          Lead Product(s) : Finasteride

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Finasteride is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 21, 2010

                          Lead Product(s) : Finasteride

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          03

                          Lead Product(s) : Finasteride

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Finasteride is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 28, 2010

                          Lead Product(s) : Finasteride

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          04

                          Lead Product(s) : Finasteride

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Finasteride is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 28, 2010

                          Lead Product(s) : Finasteride

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          05

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Akums gains rights for patented topical formulation, Therapy-07, for the Indian market which combines three medicaments (finasteride,latanoprost,minoxidil) to combat alopecia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          October 16, 2024

                          Lead Product(s) : Finasteride,Latanoprost,Minoxidil

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Akums Drugs & Pharmaceuticals Ltd

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          06

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : The combined company will focus on the R&D and commercialization of proprietary science and technologies for therapeutics, including Entadfi, a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a PDE5...

                          Product Name : Entadfi

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          December 18, 2023

                          Lead Product(s) : Finasteride,Tadalafil

                          Therapeutic Area : Urology

                          Highest Development Status : Approved FDF

                          Sponsor : Blue Water Vaccines

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          07

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Under the collaboration, Blue Water Biotech and IQVIA will market Blue Water’s commercial portfolio including, Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for benign prostatic hyperplasia and Zontivity (vorapaxar).

                          Product Name : Entadfi

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          June 21, 2023

                          Lead Product(s) : Finasteride,Tadalafil

                          Therapeutic Area : Urology

                          Highest Development Status : Approved FDF

                          Sponsor : IQVIA

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : The acquisition transforms the Company into a broader pharmaceutical company spanning multiple sectors by including ENTADFI (finasteride), an oral, once daily treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a PDE5 i...

                          Product Name : Entadfi

                          Product Type : Miscellaneous

                          Upfront Cash : $20.0 million

                          April 20, 2023

                          Lead Product(s) : Finasteride,Tadalafil

                          Therapeutic Area : Urology

                          Highest Development Status : Approved FDF

                          Sponsor : Blue Water Vaccines

                          Deal Size : $100.0 million

                          Deal Type : Agreement

                          blank

                          09

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : ENTADFI (finasteride and tadalafil) capsules for oral use, a new treatment for urinary tract symptoms caused by an enlarged prostate called benign prostatic hyperplasia.

                          Product Name : Entadfi

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 13, 2021

                          Lead Product(s) : Finasteride,Tadalafil

                          Therapeutic Area : Urology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Under the terms of the licensing agreement, Hikma will be responsible for the registration and commercialisation of the product Finjuve, in certain MENA markets and Almirall will be responsible for product supply.

                          Product Name : Finjuve

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          November 01, 2021

                          Lead Product(s) : Finasteride

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Hikma Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank